Skip to main content

Fetal Medicine Foundation Algorithm Can Predict Preeclampsia

Medically reviewed by Carmen Pope, BPharm. Last updated on May 8, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, May 8, 2024 -- The first-trimester Fetal Medicine Foundation (FMF) screening test predicts 63.1 percent of preterm preeclampsia cases and 77.3 percent of early-onset preeclampsia cases, according to a study published online May 6 in Hypertension.

Paul Guerby, M.D., Ph.D., from Université Laval in Quebec City, and colleagues conducted a prospective cohort study of nulliparous women recruited at 11 to 14 weeks to examine the FMF preterm preeclampsia screening test. Receiver operating characteristic curves were used to estimate the detection rate (sensitivity) and the false-positive rate (1-specificity) for preterm and early-onset preeclampsia based on the FMF screening test and according to criteria from the American College of Obstetricians and Gynecologists.

A total of 7,554 participants were recruited, of whom 97 percent remained eligible after 20 weeks. Overall, 0.9 and 0.3 percent developed preterm preeclampsia and early-onset preeclampsia, respectively. The researchers found that the detection rate was 63.1 and 77.3 percent for preterm preeclampsia and early-onset preeclampsia, respectively, using the FMF algorithm (cutoff of ≥1 in 110 for preterm preeclampsia), at a false-positive rate of 15.8 percent. The equivalent detection rates would have been 61.5 and 59.1 percent, respectively, using the American College of Obstetricians and Gynecologists criteria, for a false-positive rate of 34.3 percent.

"The FMF preeclampsia algorithm should be prioritized over other currently used algorithms," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2024

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.